Physician profile
Davis Holt
NPI 1629096615
$1,575.76
in general payments reported to CMS, 2019-2025
22 companies · $46.57 in 2025
The $46.57 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.74 · 2022: $32.24 · 2023: $394 · 2024: $1,031 · 2025: $46.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201 · Travel and Lodging: $226 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.91 |
| Travel and Lodging | $225.87 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $498.80 | 2024 | |
| Medtronic, INC. | $337.63 | 2023 | Intellis Adaptivestim, Synchromedii |
| Scilex Pharmaceuticals INC. | $114.80 | 2023-2024 | Ztlido |
| Abbvie INC. | $70.75 | 2024 | |
| Abbott Laboratories | $66.76 | 2024 | Proclaim |
| Collegium Pharmaceutical, INC. | $66.45 | 2023-2024 | Xtampza, Belbuca |
| Horizon Therapeutics Plc | $54.87 | 2021 | |
| Si-Bone, INC. | $41.70 | 2024 | |
| Pfizer INC. | $37.86 | 2021-2024 | |
| Valinor Pharma, LLC | $35.81 | 2024 | Movantik |
| Virtus Pharmaceuticals LLC | $30.81 | 2024-2025 | Levorphanol Tartrate |
| Nevro Corp. | $27.55 | 2024 | Senza |
| Spr Therapeutics, INC | $25.40 | 2024 | Sprint Pns System |
| Stryker Corporation | $24.88 | 2024 | Mild Device Kit |
| Vertos Medical, INC. | $24.76 | 2024 | Mild Device Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $20.57 | 2024 | Ha Minuteman G3-R |
| Relievant Medsystems, INC. | $18.27 | 2023 | Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.93 | 2022 | |
| Novo Nordisk INC | $16.24 | 2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $16.04 | 2025 | Mounjaro, Zepbound |
| Currax Pharmaceuticals LLC | $14.31 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.57 | 2024 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davis Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.